Tofacitinib in juvenile idiopathic arthritis

Research output: Contribution to journalComment/debate (Academic Journal)peer-review

5 Citations (Scopus)
Original languageEnglish
Pages (from-to)1943-1945
Number of pages3
JournalLancet
Volume398
Issue number10315
Early online date9 Nov 2021
DOIs
Publication statusPublished - 27 Nov 2021

Bibliographical note

Funding Information:
SLNC receives support from the Wellcome Trust (203918/Z/16/Z) for a doctoral training fellowship. AVR has received speaker's fees, served on advisory boards, and received consulting fees unrelated to the topic of this Comment from AbbVie, Novartis, Roche, Swedish Orphan Biovitrum AB, and Union Chimique Belge, and serves on an advisory board or steering committee for Eli Lilly on trials of baricitinib in children with rheumatic diseases.

Cite this